Tacrolimus in ophthalmology Waris Abdul1, Nagpal G K2, Nagpal Gargi3,*, Akhtar Naheed4 1Assistant Professor, AMUIO, Aligarh 2Nagpal, Senior Eye Surgeon, Nagpal Eye Care & Research Centre, Aligarh 3Junior Resident II, AMUIO, Aligarh 4Eye Surgeon, Gandhi Eye Hospital, Aligarh *Corresponding Author: Email: garginagpal@rediffmail.com
Online published on 13 May, 2015. Abstract Tacrolimus is a 23 member cyclic macrolide lactone and was isolated from Streptomyces tsukubaensis in 1984.[1] it has been shown in vitro and in vivo to be a potent immunosuppressive agent. It is 100 times more powerful than cyclosporine in vitro in inhibiting T-cell proliferative responses, including mixed lymphocyte reactivity and cytotoxic T-cell generation. This immunomodulator has increasing number of implications in various aspects of ophthalmological conditions, the battle against them so far having been fought with corticosteroids, which are themselves a double edged sword. In this article we will be going through various studies which have thrown light on the future potential of applications of tacrolimus in ophthalmology.[2] Top Keywords Allergic conjunctivitis, dry eye disease, tacrolimus, immunomodulation, uveitis, graft versus host disease. Top |